420 related articles for article (PubMed ID: 26833433)
1. Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18.
Carvalho S; Levi-Schaffer F; Sela M; Yarden Y
Br J Pharmacol; 2016 May; 173(9):1407-24. PubMed ID: 26833433
[TBL] [Abstract][Full Text] [Related]
2. Cancer Immunotherapy: The Dawn of Antibody Cocktails.
Marrocco I; Romaniello D; Yarden Y
Methods Mol Biol; 2019; 1904():11-51. PubMed ID: 30539465
[TBL] [Abstract][Full Text] [Related]
3. Promises and pitfalls for recombinant oligoclonal antibodies-based therapeutics in cancer and infectious disease.
Corti D; Kearns JD
Curr Opin Immunol; 2016 Jun; 40():51-61. PubMed ID: 26995095
[TBL] [Abstract][Full Text] [Related]
4. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
5. [Mimicking polyclonal immune response in therapy: from combination of two monoclonal antibodies to oligoclonal antibody-based mixtures].
Larbouret C; Poul MA; Chardès T
Med Sci (Paris); 2019 Dec; 35(12):1083-1091. PubMed ID: 31903921
[TBL] [Abstract][Full Text] [Related]
6. Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells.
Marcucci F; Bellone M; Rumio C; Corti A
MAbs; 2013; 5(1):34-46. PubMed ID: 23211740
[TBL] [Abstract][Full Text] [Related]
7. Future prospects of monoclonal antibodies as magic bullets in immunotherapy.
Maleki LA; Baradaran B; Majidi J; Mohammadian M; Shahneh FZ
Hum Antibodies; 2013; 22(1-2):9-13. PubMed ID: 24284304
[TBL] [Abstract][Full Text] [Related]
8. Antibodies in oncology.
Pillay V; Gan HK; Scott AM
N Biotechnol; 2011 Sep; 28(5):518-29. PubMed ID: 21473941
[TBL] [Abstract][Full Text] [Related]
9. [Antibody-dependent cellular cytotoxicity in the immunotherapeutic mechanisms of anti-EGFR monoclonal antibody].
Shimodaira H; Komine K; Soeda H; Ishioka C
Gan To Kagaku Ryoho; 2010 May; 37(5):795-8. PubMed ID: 20495309
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic antibodies against cancer.
Adler MJ; Dimitrov DS
Hematol Oncol Clin North Am; 2012 Jun; 26(3):447-81, vii. PubMed ID: 22520975
[TBL] [Abstract][Full Text] [Related]
11. [The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases].
Alfaro C; Murillo O; Tirapu I; Azpilicueta A; Huarte E; Arina A; Arribillaga L; Pérez-Gracia JL; Bendandi M; Prieto J; Lasarte JJ; Melero I
An Sist Sanit Navar; 2006; 29(1):77-96. PubMed ID: 16670731
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the synergistic neutralizing effect of anti-botulinum oligoclonal antibody preparations.
Diamant E; Lachmi BE; Keren A; Barnea A; Marcus H; Cohen S; David AB; Zichel R
PLoS One; 2014; 9(1):e87089. PubMed ID: 24475231
[TBL] [Abstract][Full Text] [Related]
13. Novel antibodies targeting immune regulatory checkpoints for cancer therapy.
Lee CS; Cragg M; Glennie M; Johnson P
Br J Clin Pharmacol; 2013 Aug; 76(2):233-47. PubMed ID: 23701301
[TBL] [Abstract][Full Text] [Related]
14. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.
Pennock GK; Chow LQ
Oncologist; 2015 Jul; 20(7):812-22. PubMed ID: 26069281
[TBL] [Abstract][Full Text] [Related]
15. The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived?
Newsome BW; Ernstoff MS
Br J Clin Pharmacol; 2008 Jul; 66(1):6-19. PubMed ID: 18503606
[TBL] [Abstract][Full Text] [Related]
16. Genetically engineered antibodies for direct antineoplastic treatment and systematic delivery of various therapeutic agents to cancer cells.
Bodey B
Expert Opin Biol Ther; 2001 Jul; 1(4):603-17. PubMed ID: 11727497
[TBL] [Abstract][Full Text] [Related]
17. Combining epitope-distinct antibodies to HER2: cooperative inhibitory effects on invasive growth.
Emde A; Pradeep CR; Ferraro DA; Ben-Chetrit N; Sela M; Ribba B; Kam Z; Yarden Y
Oncogene; 2011 Apr; 30(14):1631-42. PubMed ID: 21132012
[TBL] [Abstract][Full Text] [Related]
18. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies.
Ascierto PA; Simeone E; Sznol M; Fu YX; Melero I
Semin Oncol; 2010 Oct; 37(5):508-16. PubMed ID: 21074066
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Antibodies in Cancer Therapy.
Gasser M; Waaga-Gasser AM
Adv Exp Med Biol; 2016; 917():95-120. PubMed ID: 27236554
[TBL] [Abstract][Full Text] [Related]
20. Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy.
Liu B; Song Y; Liu D
J Hematol Oncol; 2017 Dec; 10(1):174. PubMed ID: 29195503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
